Gizem Çil, Ömer Araz, Buğra Kerget, Esra Laloglu, Alperen Aksakal, Elif Yılmazel Uçar, Leyla Sağlam
{"title":"Serum Ang 1, Ang 1-7, and Mas levels as potential biomarkers in obstructive sleep apnea syndrome.","authors":"Gizem Çil, Ömer Araz, Buğra Kerget, Esra Laloglu, Alperen Aksakal, Elif Yılmazel Uçar, Leyla Sağlam","doi":"10.1080/17520363.2025.2525059","DOIUrl":null,"url":null,"abstract":"<p><strong>Aims: </strong>In obstructive sleep apnea (OSA), the balance between inflammatory and anti-inflammatory responses is disrupted. This study examined the association between serum angiotensin 1 (Ang 1), angiotensin 1-7 (Ang 1-7), and Mas receptor levels and OSA severity.</p><p><strong>Material and methods: </strong>A total of 190 subjects underwent polysomnography and serum analysis for Ang 1, Ang 1-7, and Mas using ELISA. Patients were classified into control, mild, moderate, and severe OSA groups based on AHI.</p><p><strong>Results: </strong>Ang 1-7, Ang 1, and serum Mas levels were significantly lower in moderate and severe OSA groups compared to control and mild OSA (<i>p</i> < 0.001). Negative correlations were found between these biomarkers and AHI (e.g. Ang 1-7: <i>R</i> = -0.597, <i>p</i> < 0.001). ROC analysis showed strong diagnostic performance: AUC was 0.864 for Ang 1-7, 0.873 for Ang 1, and 0.837 for Mas, with sensitivity of 98%, 98%, and 97%, respectively.</p><p><strong>Conclusion: </strong>Reduced levels of Ang 1-7, Ang 1, and Mas are associated with increased OSA severity. These biomarkers demonstrated high diagnostic value and may be useful in stratifying patients with moderate-to-severe OSA.</p>","PeriodicalId":9182,"journal":{"name":"Biomarkers in medicine","volume":" ","pages":"613-621"},"PeriodicalIF":1.9000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomarkers in medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17520363.2025.2525059","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0
Abstract
Aims: In obstructive sleep apnea (OSA), the balance between inflammatory and anti-inflammatory responses is disrupted. This study examined the association between serum angiotensin 1 (Ang 1), angiotensin 1-7 (Ang 1-7), and Mas receptor levels and OSA severity.
Material and methods: A total of 190 subjects underwent polysomnography and serum analysis for Ang 1, Ang 1-7, and Mas using ELISA. Patients were classified into control, mild, moderate, and severe OSA groups based on AHI.
Results: Ang 1-7, Ang 1, and serum Mas levels were significantly lower in moderate and severe OSA groups compared to control and mild OSA (p < 0.001). Negative correlations were found between these biomarkers and AHI (e.g. Ang 1-7: R = -0.597, p < 0.001). ROC analysis showed strong diagnostic performance: AUC was 0.864 for Ang 1-7, 0.873 for Ang 1, and 0.837 for Mas, with sensitivity of 98%, 98%, and 97%, respectively.
Conclusion: Reduced levels of Ang 1-7, Ang 1, and Mas are associated with increased OSA severity. These biomarkers demonstrated high diagnostic value and may be useful in stratifying patients with moderate-to-severe OSA.
期刊介绍：
Biomarkers are physical, functional or biochemical indicators of physiological or disease processes. These key indicators can provide vital information in determining disease prognosis, in predicting of response to therapies, adverse events and drug interactions, and in establishing baseline risk. The explosion of interest in biomarker research is driving the development of new predictive, diagnostic and prognostic products in modern medical practice, and biomarkers are also playing an increasingly important role in the discovery and development of new drugs. For the full utility of biomarkers to be realized, we require greater understanding of disease mechanisms, and the interplay between disease mechanisms, therapeutic interventions and the proposed biomarkers. However, in attempting to evaluate the pros and cons of biomarkers systematically, we are moving into new, challenging territory.
Biomarkers in Medicine (ISSN 1752-0363) is a peer-reviewed, rapid publication journal delivering commentary and analysis on the advances in our understanding of biomarkers and their potential and actual applications in medicine. The journal facilitates translation of our research knowledge into the clinic to increase the effectiveness of medical practice.
As the scientific rationale and regulatory acceptance for biomarkers in medicine and in drug development become more fully established, Biomarkers in Medicine provides the platform for all players in this increasingly vital area to communicate and debate all issues relating to the potential utility and applications.
Each issue includes a diversity of content to provide rounded coverage for the research professional. Articles include Guest Editorials, Interviews, Reviews, Research Articles, Perspectives, Priority Paper Evaluations, Special Reports, Case Reports, Conference Reports and Company Profiles. Review coverage is divided into themed sections according to area of therapeutic utility with some issues including themed sections on an area of topical interest.
Biomarkers in Medicine provides a platform for commentary and debate for all professionals with an interest in the identification of biomarkers, elucidation of their role and formalization and approval of their application in modern medicine. The audience for Biomarkers in Medicine includes academic and industrial researchers, clinicians, pathologists, clinical chemists and regulatory professionals.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
